Original Articles and Brief Reports

Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials

Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, and Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA
School of Mathematics, University of Minnesota, Minneapolis, MN, USA
Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
INSERM Centre d'Investigation Clinique CIC 0802, Centre Hospitalier Universitaire de Poitiers, France
Laboratoire d'Hématologie et Service des Maladies du Sang, CHU de Bordeaux, Bordeaux, France, Universite Victor Ségalen Bordeaux 2, Bordeaux, France, and INSERM U876, Bordeaux, France
Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, and Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA
Vol. 97 No. 10 (2012): October, 2012 https://doi.org/10.3324/haematol.2012.062844